Renal Cell Carcinoma

Preliminary data shows renal cancer drug is safe and well tolerated

Published in Drug Week, November 11th, 2005

Oxford BioMedica (OXB.L) announces preliminary data from the phase II trial of TroVax in renal cell carcinoma (RCC) that shows the drug is safe and well tolerated in this patient group and induces a strong antitumor immune response against the 5T4 tumor antigen.

Some of the data was referenced in a presentation made by the principal investigator for this phase II trial at the World Vaccine Congress.

The phase II trial in RCC is being conducted at the New York-Presbyterian Hospital in New York, USA, under an approved investigational new drug protocol. The principal investigator for the trial is Dr Howard Kaufmann of the New York-Presbyterian Hospital,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry